Cadila Pharmaceuticals expand oncology portfolio with biosimilar cancer drug Bevaro™

Bevaro

Ahmedabad-based Cadila Pharmaceuticals Limited recently announced the launch of Bevasizumab biosimilar for the domestic market.

Bevacizumab biosimilar is a humanized monoclonal antibody, recommended in multiple indications and will be launched under the brand name Bevaro™.

Bevasizumab is used in the treatment of multiple cancers which are common in India like Ovarian Cancer, Glioblastoma Multiforme (a type of Brain cancer), Colorectal Cancer, Breast Cancer, Lung Cancer, Cervical Cancer and Kidney Cancer.

In a commitment to further strengthen the oncology portfolio Cadila’s Bevaro™ will be made available in a single-dose vial of two strengths, 100 mg, and 400mg.

The pharma giant has always been focused on making sure high quality, affordable, and life-saving treatments are within the reach of patients.

Biosimilar products like Bevaro™ are safe and more efficacious compared to conventional treatment medicines. Cadila plans to launch multiple biosimilar products this year for the Indian Market.

Cadila Pharmaceuticals Ltd. (www.cadilapharma.com) is one of the largest privately-held pharmaceutical companies in India.

It has recently concluded and cleared USFDA inspection successfully in February 2020. Over the past six decades, Cadila Pharmaceuticals has been engaged in the development and manufacturing of affordable medicines and in making them available for patients across the world.

Its innovation-driven drug discovery processes ensure the health and well-being of people around the world.